PreciseDx®, a NYC-based innovator in oncology diagnostics leveraging Synthetic Intelligence, raised $20.7M in Collection B funding.
The spherical was led by Eventide Asset Administration, with participation from Labcorp, Quest Diagnostics, and GenHenn Capital Enterprise, together with current traders.
The corporate intends to make use of the funds to assist expanded commercialization efforts for PreciseBreast™ danger evaluation.
PreciseDx is innovating oncology diagnostics by leveraging Synthetic Intelligence for morphology-driven illness evaluation. Combining AI with the patented Morphology Function Array® (MFA), it gives entry to illness insights and correct, actionable intelligence for extra complete decision-making all through the most cancers care continuum.
The funding follows a variety of key achievements by PreciseDx, together with completion of two profitable validation research (analytical and scientific); receipt of CLIA Normal approval and CLEP NYSDOH evaluation on the PreciseBreast™ evaluation; a Price Impression Research printed by the Journal of Medical Economics; and the addition of latest key collaborations, akin to UCLA, COTA and Baptist Well being South Florida, and Baylor Scott & White Well being.
FinSMEs
21/08/2024
